Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us? — Gianna Fabbri (2009) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Shared by
Aldo Maggioni
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Article
2009
en
Authors
GF
Gianna Fabbri
Aldo Maggioni
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2014
LFP and oscillations—what do they tell us?
Karl Friston
,
André M. Bastos
,
Dimitris A. Pinotsis
,
Vladimir Litvak
Article
2023
Sample, Fuzzy and Distribution Entropies of Heart Rate Variability: What Do They Tell Us on Cardiovascular Complexity?
Paolo Castiglioni
,
Giampiero Merati
,
Gianfranco Parati
,
Andrea Faini
Article
2010
A Tale of Two Depressions: What do the New Data Tell Us?
Barry Eichengreen
Article
2023
[What does excess mortality tell us?]
Olaf M. Dekkers
,
Mark de Boer
,
Frits R. Rosendaal
PubMed
Article
2024
Global variations in gallbladder cancer incidence: What do recorded data and national estimates tell us?
Marion Piñeros
,
Jérôme Vignat
,
Murielle Colombet
,
Mathieu Laversanne
,
Catterina Ferreccio
,
Katy Heise
,
Sharayu Mhatre
,
Jill Koshiol
,
Freddie Ian Bray
Discussion(0)
No comments yet. Be the first to comment.